drugset / Trial / NCT01916265
Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages
RandomizedParallel-groupOpen-labelBasic science
Summary
The ultimate goal of the PCDIAB project is to develop a bi-hormonal pump (insulin and glucagon) substituting for the pancreas and facilitating tight euglycemic control in patients with T1DM.
Timeline
- Start
- 2013-08
- Primary completion
- 2013-11
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glucagon | Peptide | 0.11 mg | — |
| Subject | Glucagon | Peptide | 0.22 mg | — |
| Subject | Glucagon | Peptide | 0.33 mg | — |
| Subject | Glucagon | Peptide | 0.44 mg | — |
| Subject | Glucagon | Peptide | 0.66 mg | — |
| Subject | Glucagon | Peptide | 1 mg | — |